STOCK TITAN

MoonLake Immunotherapeutics - $MLTX STOCK NEWS

Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: $MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MoonLake Immunotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MoonLake Immunotherapeutics's position in the market.

Rhea-AI Summary
MoonLake Immunotherapeutics to host Capital Markets Day on Sep 11. Will discuss psoriatic arthritis market and upcoming trial results. Positive top-line results from Phase 2 MIRA trial in June. External speaker presentation. Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
-
Rhea-AI Summary
MoonLake Immunotherapeutics achieves positive results in Phase 2 MIRA trial for hidradenitis suppurativa, completes randomization in Phase 2 ARGO trial for psoriatic arthritis, and raises $460 million in public follow-on offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
MoonLake Immunotherapeutics AG has completed patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA). The randomization target of 200 patients was achieved several weeks ahead of schedule. The top-line 12-week results of the ARGO trial for the novel IL-17A and IL-17F inhibiting Nanobody® sonelokimab are expected in the first half of November 2023, ahead of the American College of Rheumatology Conference. MoonLake also announced a Capital Markets Day on September 11th, 2023, to discuss the PsA market and share expectations on the ARGO readout and an update on the MIRA trial in Hidradenitis Suppurativa (HS). The top-line 24-week data readout for the MIRA trial is now expected in mid-October 2023, following the successful top-line 12-week data readout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
MoonLake Immunotherapeutics

Nasdaq:MLTX

MLTX Rankings

MLTX Stock Data

2.80B
23.47M
9.42%
96.64%
12.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ZUG

About MLTX

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.